Research article

Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis

Patrick H Dessein¹, Barry I Joffe² and Sham Singh³

¹Department of Rheumatology, Johannesburg Hospital and Milpark Hospital, Parktown, University of the Witwatersrand, Johannesburg, South Africa
²Centre for Diabetes and Endocrinology, Houghton, University of the Witwatersrand, Johannesburg, South Africa
³Lancet Laboratories, Richmond, Johannesburg, South Africa

Corresponding author: Patrick H Dessein, Dessein@lancet.co.za

Received: 9 Jan 2005 Revisions requested: 24 Jan 2005 Revisions received: 2 Feb 2005 Accepted: 15 Feb 2005 Published: 24 Mar 2005

Arthritis Research & Therapy 2005, 7:R634-R643 (DOI 10.1186/ar1717)

Abstract

Cardiovascular event rates are markedly increased in rheumatoid arthritis (RA), and RA atherogenesis remains poorly understood. The relative contributions of traditional and nontraditional risk factors to cardiovascular disease in RA await elucidation. The present study comprises three components. First, we compared biomarkers of endothelial dysfunction (vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule [ICAM]-1 and endothelial leucocyte adhesion molecule [ELAM]-1) in 74 RA patients and 80 healthy control individuals before and after controlling for traditional and nontraditional cardiovascular risk factors, including high-sensitivity C-reactive protein (hs-CRP), IL-1, IL-6 and tumor necrosis factor-α. Second, we investigated the potential role of an extensive range of patient characteristics in endothelial dysfunction in the 74 RA patients. Finally, we assessed associations between biomarkers of endothelial dysfunction and ultrasonographically determined common carotid artery intima–media thickness and plaque in RA. The three biomarkers of endothelial dysfunction, as well as hs-CRP, IL-1, IL-6 and tumor necrosis factor-α, were higher in patients than in control individuals (P < 0.0001). Patients were also older, exercised less and had a greater waist circumference, blood pressure and triglyceride levels (P ≤ 0.04). Five patients had diabetes. Differences in endothelial function were no longer significant between patients and controls (P = 0.08) only after both traditional and nontraditional cardiovascular risk factors were controlled for. In the 74 RA patients, IL-6 predicted levels of all three biomarkers (P ≤ 0.03), and rheumatoid factor titres and low glomerular filtration rate (GFR) both predicted levels of VCAM-1 and ICAM-1, independent of traditional cardiovascular risk factors (P ≤ 0.02). VCAM-1 was associated with common carotid artery intima–media thickness (P = 0.02) and plaque (P = 0.04) in RA. Patients had impaired endothelial function, less favourable traditional cardiovascular risk factor profiles, and higher circulating concentrations of hs-CRP and cytokines compared with healthy control individuals. Both traditional and nontraditional cardiovascular risk factors contributed to the differences in endothelial function between RA patients and healthy control individuals. IL-6, rheumatoid factor titres and low GFR were independently predictive of endothelial dysfunction in RA. Disease-modifying agents that effectively suppress both cytokine and rheumatoid factor production, and interventions aimed at preserving renal function may attenuate cardiovascular risk in RA.

Introduction

Cardiovascular disease is an increasingly recognized contributor to excess morbidity and mortality in rheumatoid arthritis (RA) [1-5]. Traditional cardiovascular risk factors do not adequately account for the extent of cardiovascular disease in RA [3,5]. Although hypertension and age are potential additional contributors to cardiovascular events in this disease [6], markers of current and cumulative inflammation (white cell counts and radiographic joint damage, respectively) are associated with ultrasonographically determined subclinical atherosclerosis [7,8] – a predictor of cardiovascular events [9].

Atherosclerosis often develops subclinically over prolonged periods of time; therefore, it may be too insensitive to show...
associations with recently acquired or temporarily active modifiable cardiovascular risk factors, such as systemic inflammation secondary to recent onset or uncontrolled RA. Clearly, other outcome variables that can identify patients at risk for cardiovascular disease at any point in time are needed in RA.

One such potential marker is endothelial dysfunction – an essential step in atherogenesis [10]. Most if not all risk factors that are related to cardiovascular disease are also associated with endothelial dysfunction, and the process is reversible with effective treatment of operative risk factors [10]. Endothelial status may be regarded as an integrated index of all atherogenic and atheroprotective factors present in an individual [10].

Several methods have been employed to assess endothelial function. Using ultrasonographically measured brachial artery flow mediated dilatation or vasodilatory responses to intrabrachial artery infusion of acetylcholine, some [11-14] but not all investigators [15] have shown impaired endothelial function in RA. Endothelial dysfunction was related to inflammation [12] and HLA-DR1 [11], and was found to improve with infliximab treatment [13]. An alternative method to assess endothelial function involves the measurement of biomarkers of endothelial activation and dysfunction (circulating vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule [ICAM]-1, and endothelial leucocyte adhesion molecule [ELAM]-1 [or selectin]) [16-20]. Elevated circulating adhesion molecules are associated with cardiovascular risk factors [17] and predict atherosclerosis and cardiovascular events [18-20]. The measurement of circulating adhesion molecules may not add much predictive information to that provided by more established risk factors in the general population [21]. In contrast, it has been reported that such biomarkers play a more important role than traditional risk factors in cardiovascular disease in RA [22,23]. Important in this context is that high circulating adhesion molecule levels may not only reflect synovial inflammation but also indicate exposure of the systemic vascular endothelium to high circulating cytokine concentrations [24].

To our knowledge, the relative impact of traditional versus nontraditional cardiovascular risk factors on endothelial dysfunction as assessed using biomarkers has not been reported in RA. The present study comprises three components. First, we compared biomarkers of endothelial dysfunction in 74 RA patients and 80 healthy control individuals before and after controlling for potential explanatory variables, including both traditional and nontraditional cardiovascular risk factors. Second, we investigated in the 74 RA patients the potential role played by an extensive range of patient characteristics in endothelial dysfunction. Finally, we assessed the association between biomarkers of endothelial dysfunction and ultrasonographically determined common carotid artery (CCA) intima–media thickness (IMT) and plaque [9].

Materials and methods
Biomarkers of endothelial dysfunction in RA patients and healthy control individuals
Seventy-six consecutive patients who fulfilled the American College of Rheumatology criteria for RA [25] were invited to participate. Only two patients refused, and the remaining 74 were included. Patients receiving lipid-lowering and antidiabetic medications were excluded. The baseline clinical and routine laboratory characteristics of the included RA patients are reported elsewhere [26]. Eighty-three individuals with no known diseases and who were not taking any medication agreed to act as controls. These were friends, patient friends and laboratory staff. Three of them were excluded because they were found to have impaired fasting glucose (plasma glucose >5.5 mmol/l); the remaining 80 were included in the study. The study was approved by the Ethics Committees for Research on Human Subjects (Medical) of the University of the Witwatersrand and the Milpark Hospital.

We recorded traditional cardiovascular risk factors in both RA patients and control individuals using previously reported methods (Table 1) [26]. We also recorded the following nontraditional cardiovascular risk factors: circulating high-sensitivity C-reactive protein (hs-CRP), cytokines (IL-1, IL-6 and tumor necrosis factor [TNF]-α), cytokine suppressant therapy (disease-modifying antirheumatic drug [DMARD] and prednisone use) and biomarkers of endothelial dysfunction (Tables 1 and 2). Blood sampling was performed on the same day that clinical data were recorded. Fasting blood samples were taken between 08:00 and 10:00 hours. All laboratory analyses except for assessments of cytokines and biomarkers of endothelial dysfunction were performed within 2 hours of sampling. These comprised lipids, hs-CRP and other laboratory tests that were performed for the second component of the study, which was conducted in the RA patients only (see below). Blood samples drawn for determination of cytokines and biomarkers of endothelial dysfunction were stored at -70°C before laboratory testing. Cytokines and adhesion molecules were measured using enzyme-linked immunosorbent assays (Hiss Diagnostics GmbH, Freiburg, Switzerland). The intra-assay and inter-assay coefficients of variation (respectively) were 5.1% and 8.6% for IL-1, 3.4% and 5.2% for IL-6, 6.9% and 7.4% for TNF-α, 3.1% and 5.2% for VCAM-1, 4.1% and 7.7% for ICAM-1, and 5.4% and 6.0% for ELAM-1.

Statistical analysis
The traditional and nontraditional risk factors were compared using the Mann–Whitney U-test (continuous variables) and the χ² test (dichotomous variables; Table 1). Apart from hs-CRP, cytokines and cytokine suppressant therapy (DMARD and glucocorticoid use), several traditional cardiovascular risk factors differed between RA patients and control individuals. The ability of traditional and nontraditional cardiovascular risk factors to account for differences in the levels of biomarkers of endothelial dysfunction between RA patients and control individuals was assessed using the stepwise multiple regression analysis.
Relationship between patient characteristics and biomarkers of endothelial dysfunction in RA patients

For the second component of the study, recorded variables other than cytokines and biomarkers of endothelial dysfunction are summarized in Tables 3 and 4. A descriptive analysis of these variables in the current cohort was previously reported [26]. Although 10 patients were on thyroxine replacement therapy and eight had subclinical hypothyroidism (thyrotropin >4 μU/ml and normal thyroxine levels) [27], none had clinical hypothyroidism (decreased thyroxine levels) at the time of the study. IgM rheumatoid factor was determined using an immunoturbidimetric test on the Olympus AU 600 analyzer. The intra-assay and inter-assay coefficients of variation for rheumatoid factor were 3.4% and 4.6%, respectively.

Statistical analysis

Associations between patient characteristics and biomarkers of endothelial dysfunction were first assessed by univariate analysis. Table 2, using RA status as the dependent variable (RA = 1, non-RA control = 0). Continuous variables that were not normally distributed were logarithmically transformed. P < 0.05 was considered statistically significant.

individuals was assessed in logistic regression models (Table 2), using RA status as the dependent variable (RA = 1, non-RA control = 0). Continuous variables that were not normally distributed were logarithmically transformed. P < 0.05 was considered statistically significant.

Table 1
Cardiovascular risk factors in RA patients and control individuals

| Risk factors                        | Controls          | Patients         | P     |
|-------------------------------------|-------------------|------------------|-------|
| **Traditional risk factors**        |                   |                  |       |
| Age (years)                         | 44 (20–87)        | 57 (27–81)       | <0.0001 |
| Women (n [%])                       | 64 (80)           | 64 (86)          | 0.3   |
| Caucasian:asian (n:n)               | 87:6              | 71:9             | 0.3   |
| Smokers (n [%])                     | 25 (31)           | 17 (23)          | 0.3   |
| Smoking (cigarettes/day)            | 0 (0–50)          | 0 (0–40)         | 0.5   |
| Alcohol users (n [%])               | 37 (47)           | 26 (35)          | 0.2   |
| Alcohol (units/week)                | 0 (0–40)          | 0 (0–35)         | 0.4   |
| Exercisers (n [%])                  | 43 (54)           | 19 (26)          | 0.0004|
| Exercise (hours/week)               | 1 (0–20)          | 0 (0–7)          | 0.0002|
| Diabetes (n [%])                    | 0 (0)             | 5 (7)            | 0.02  |
| Body mass index (kg/m²)             | 24.3 (17.9–33.8)  | 23.7 (17.9–38.3) | 1.0   |
| Waist (cm)                          | 81 (60–109)       | 85 (66–120)      | 0.01  |
| SBP (mmHg)                          | 115 (83–150)      | 123 (98–164)     | <0.0001|
| DBP (mmHg)                          | 71 (47–100)       | 82 (67–109)      | <0.0001|
| Total cholesterol (mmol/l)          | 5.3 (2.1–7.9)     | 5.1 (3.5–7.5)    | 0.4   |
| HDL-cholesterol (mmol/l)            | 1.5 (0.4–2.3)     | 1.6 (0.8–2.6)    | 0.4   |
| Triglycerides (mmol/l)              | 1.0 (0.5–4.7)     | 1.2 (0.5–2.6)    | 0.04  |
| **Nontraditional risk factors**     |                   |                  |       |
| hs-CRP (mg/l)                       | 1.6 (0.3–8.9)     | 10.8 (0.3–256)   | <0.0001|
| IL-1 (pg/ml)                        | 0.7 (0–42.7)      | 3.5 (0.1–323)    | <0.0001|
| IL-6 (pg/ml)                        | 0.8 (0.1–8.2)     | 5.4 (0.5–186.3)  | <0.0001|
| TNF-α (pg/ml)                       | 0.2 (0.2–32.6)    | 3.0 (0.3–93.2)   | <0.0001|
| **Cytokine suppressant therapy**    |                   |                  |       |
| DMARD use (n [%])                   | 0 (0)             | 56 (76)          | <0.0001|
| Prednisone use (n [%])              | 0 (0)             | 11 (15)          | 0.0003|

Results are expressed as median (range) unless indicated otherwise. Data were analyzed using the Mann–Whitney U-test (continuous variables) or the χ² test (dichotomous variables). DBP, diastolic blood pressure; DMARD, disease-modifying antirheumatic drug; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; RA, rheumatoid arthritis; SBP, systolic blood pressure; TNF, tumour necrosis factor.
Biomarkers of endothelial dysfunction in rheumatoid arthritis patients and control individuals

| Marker         | Controls | Patients       | Unadjusted   | P (multivariable adjusted) |
|----------------|----------|----------------|--------------|---------------------------|
|                |          |                | Model 1<sup>a</sup> | Model 2<sup>b</sup> | Model 3<sup>c</sup> | Model 4<sup>d</sup> |
| VCAM-1 (pg/ml) | 506 (253–1067) | 747 (391–2077) | <0.0001       | <0.0001       | <0.0001       | 0.08          |
| ICAM-1 (pg/ml) | 231 (82–857)   | 366 (135–993)  | <0.0001       | 0.0002        | <0.0001       | 0.0005        | 0.08          |
| ELAM-1 (pg/ml) | 48 (7–178)    | 58 (12–149)    | <0.0001       | 0.02          | 0.02          | 0.7           | 0.08          |

Results are expressed as median (range). Unadjusted comparisons were done using the Mann–Whitney U-test and adjustments for potentially explanatory variables were made using logistic regression models. <sup>a</sup>Adjusted for disease-modifying antirheumatic drug and prednisone use. <sup>b</sup>Adjusted for traditional risk factors (age; sex; race; smoking, alcohol and exercising status; diabetes; waist; systolic blood pressure; total cholesterol; high-density lipoprotein cholesterol; triglycerides). <sup>c</sup>Adjusted for nontraditional risk factors (high sensitivity C-reactive protein, interleukin IL-1, IL-6 and tumour necrosis factor-α). <sup>d</sup>Adjusted for traditional and nontraditional risk factors. ELAM, endothelial leukocyte adhesion molecule; ICAM, intercellular adhesion molecule; VCAM, vascular adhesion molecule.

analyses comprising the Spearman correlation coefficients (continuous variables; Table 3) and the Mann–Whitney U-test (dichotomous variables; Table 4). Because many univariate analyses were conducted in this component of the study, P < 0.01 was considered statistically significant. Because IL-6, rheumatoid factor and low glomerular filtration rate (GFR) were associated with biomarkers of endothelial dysfunction, their potential roles as predictors of endothelial dysfunction were further assessed after controlling for traditional cardiovascular risk factors in multivariable regression models (Table 5). Continuous variables that were not normally distributed were logarithmically transformed. In these multivariable models, P < 0.05 was considered statistically significant.

**Associations between biomarkers of endothelial dysfunction and common carotid artery intima–media thickness and plaque in RA patients**

The CCAs were evaluated using high resolution B-mode ultrasound. Details of this investigation in the present cohort were previously reported [26].

**Statistical analysis**
The associations between biomarkers of endothelial dysfunction and CCA IMT and plaque were determined using the Spearman correlation coefficient and the Mann–Whitney U-test, respectively. P < 0.05 was considered statistically significant.

**Results**

**Biomarkers of endothelial dysfunction in RA patients and healthy control individuals**
The recorded baseline characteristics in the RA patients and control individuals comprised traditional cardiovascular risk factors, hs-CRP and cytokines (Table 1). RA patients were younger, exercised less, had a higher waist circumference, higher systolic and diastolic blood pressures, and higher triglyceride levels than did control individuals. Five RA patients had diabetes that was being treated with dietary intervention only. With regard to nontraditional cardiovascular risk factors, hs-CRP, IL-1, IL-6 and TNF-α concentrations were higher in patients than in control individuals, and DMARD and prednisone were used by 56 and 11 RA patients, respectively. No patient was being treated or had been treated with biological agents at the time of the study.

Results for biomarkers of endothelial dysfunction in patients and control individuals are shown in Table 2. In univariate analysis, all three biomarkers of endothelial dysfunction (VCAM-1, ICAM-1 and ECAM-1) were higher in patients than in control individuals. These differences remained significant after controlling for cytokine suppressant agent (DMARD and prednisone) use (model 1) or traditional cardiovascular risk factors (model 2). After controlling for nontraditional cardiovascular risk factors, the differences in ELAM-1 between patients and control individuals were no longer significant (model 3). When traditional and nontraditional cardiovascular risk factors were simultaneously controlled for, the differences in levels of all three biomarkers of endothelial dysfunction were no longer significant between patients and control individuals (model 4).

**Relationship between patient characteristics and biomarkers of endothelial dysfunction in RA patients**

In univariate analysis, VCAM-1 was related to rheumatoid factor titres and low GFR, ICAM-1 to rheumatoid factor titres and IL-6, and ELAM-1 to IL-6 (Table 4). None of the other recorded baseline characteristics in the 74 RA patients were associated with biomarkers of endothelial dysfunction (Tables 4 and 5).

After controlling for traditional cardiovascular risk factors in multivariable regression models, IL-6 was predictive of all three biomarkers of endothelial dysfunction, and rheumatoid factor titre and low GFR were both predictive of VCAM-1 and ICAM-1 (Table 5). Additional controlling for thyrotropin levels did not materially alter these models (data not shown).

**Associations between biomarkers of endothelial dysfunction and common carotid artery intima–media thickness and plaque in RA patients**
As previously reported, the median (range) CCA IMT was 0.654 mm (0.496–1.150 mm), and 23 (31%) patients had
Table 3

Spearman correlations among biomarkers and potential cardiovascular risk factors

| Cardiovascular risk factor            | VCAM-1 (pg/ml) | ICAM-1 (pg/ml) | ELAM-1 (pg/ml) |
|---------------------------------------|----------------|----------------|----------------|
| **Demographic**                       |                |                |                |
| Age (years)                           | 0.279          | 0.149          | 0.148          |
| **Lifestyle**                          |                |                |                |
| Smoking (cigarettes/day)              | 0.209          | 0.253          | 0.062          |
| Alcohol (units/week)                  | 0.209          | 0.112          | -0.072         |
| Exercise (hours/week)                 | 0.034          | 0.085          | -0.055         |
| **Systemic inflammation**             |                |                |                |
| hs-CRP (mg/l)                         | 0.289          | 0.189          | 0.217          |
| ESR (mm/hour)                         | 0.217          | 0.175          | 0.195          |
| Disease duration (years)              | 0.138          | 0.069          | 0.079          |
| **Disease severity**                  |                |                |                |
| Radiographic score                    | 0.157          | -0.012         | 0.092          |
| Rheumatoid factor (IU/ml)             | 0.319**        | 0.363**        | 0.290          |
| **Cytokines**                         |                |                |                |
| TNF-α (pg/ml)                         | 0.107          | 0.204          | 0.019          |
| IL-1 (pg/ml)                          | -0.123         | -0.030         | -0.120         |
| IL-6 (pg/ml)                          | 0.248          | 0.298*         | 0.359**        |
| **Drug therapy**                      |                |                |                |
| Current prednisone dose (mg/day)      | 0.156          | 0.152          | 0.279          |
| Cumulative prednisone dose (mg)       | 0.042          | 0.008          | 0.071          |
| Cumulative pulsed MP (mg)             | -0.051         | -0.155         | -0.096         |
| **Metabolic syndrome**                |                |                |                |
| Waist circumference (cm)              | 0.036          | 0.249          | 0.127          |
| SBP (mmHg)                            | 0.159          | 0.011          | 0.019          |
| DBP (mmHg)                            | -0.042         | -0.073         | -0.097         |
| HDL-cholesterol (mmol/l)              | -0.093         | -0.103         | -0.091         |
| Triglycerides (mmol/l)                | 0.186          | 0.181          | 0.079          |
| QUICKI                                 | -0.088         | -0.035         | -0.019         |
| Uric acid (mmol/l)                    | 0.208          | 0.271          | 0.280          |
| **Others**                            |                |                |                |
| Haemoglobin (g/dl)                    | -0.139         | -0.130         | -0.093         |
| Leucocytes (× 10⁹/l)                  | -0.017         | -0.096         | 0.199          |
plaque [26]. Twenty-one (28%) patients had a CCA IMT under 0.600 mm and no plaque. The role of clinical and routine laboratory characteristics as predictors of common carotid atherosclerosis in the present cohort was also previously reported [26]. VCAM-1 concentrations correlated with the CCA IMT ($r_s = 0.280$; $P = 0.016$) and were higher in patients with plaque than in those without plaque (769 pg/ml [391–2073 pg/ml] versus 703 pg/ml [445–2001 pg/ml]; $P = 0.043$). The associations between CCA findings and other biomarkers did not achieve statistical significance.

**Discussion**

**Biomarkers of endothelial dysfunction in RA patients and healthy control individuals**

We found that biomarkers of endothelial dysfunction were markedly higher in RA patients than in healthy control individuals. Increased circulating adhesion molecule concentrations have been reported in RA [23,24,28,29]. Our patients also had higher hs-CRP and IL-1, IL-6 and TNF-α concentrations than did control individuals, but these nontraditional cardiovascular risk factors did not fully account for the differences in biomarkers of endothelial dysfunction between patients and control individuals. Indeed, the RA patients also had generally less favourable traditional cardiovascular risk factor profiles than healthy control individuals.

The younger age of the healthy control individuals included reflects the difficulties in recruiting healthy aged persons who are not taking any medication. Hence, we controlled for age as well as other traditional cardiovascular risk factors when assessing the differences in biomarkers of endothelial dysfunction between patients and control individuals. Of interest, the body mass indices were similar in both groups, but patients had higher waist circumference, blood pressure and triglyceride levels. The latter are features of the metabolic syndrome [5,30]. Although differences in age and exercise habits might have contributed to these findings, features of the metabolic syndrome also cluster in RA because of inflammation-induced insulin resistance [5,30].

In multivariable models, traditional cardiovascular risk factors attenuated the differences in biomarkers of endothelial dysfunction between patients and control individuals to a lesser extent than did nontraditional cardiovascular risk factors. However, the differences in endothelial function between patients and control individuals were no longer significant only after both traditional and nontraditional cardiovascular risk factors had been controlled for. Our results also show the need for comprehensive assessment of cardiovascular risk factors in healthy individuals when comparing their endothelial function with that in RA patients.

**Relationship between patient characteristics and biomarkers of endothelial dysfunction in RA patients**

We investigated the potential role of an extensive range of patient characteristics in endothelial dysfunction in RA. IL-6, rheumatoid factor titre and low GFR predicted endothelial dysfunction, as assessed using biomarkers.

### Table 3 (Continued)

| Biomarker                          | Spearman Correlation Coefficient | *P* Value |
|-----------------------------------|----------------------------------|-----------|
| Polymorphonuclear cells ($\times 10^6/l$) | 0.041                            | -0.092    |
| Platelets ($10^9/l$)              | -0.025                           | 0.142     |
| Homocysteine ($\mu$mol/l)         | 0.124                            | 0.236     |
| Thyrotropin ($\mu$IU/ml)           | -0.132                           | 0.007     |
| LDL-cholesterol (mmol/l)          | -0.139                           | -0.078    |
| Apolipoprotein(a) (mg/l)          | 0.097                            | 0.004     |
| GFR (ml/min)                      | -0.285*                          | -0.144    |
| Urinary albumin/creatinine (mg/mmol) | -0.182                         | -0.163    |

DBP, diastolic blood pressure; ELAM, endothelial leukocyte adhesion molecule; ESR, erythrocyte sedimentation rate; GFR, glomerular filtration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; ICAM, intercellular adhesion molecule; IL, interleukin; LDL, low-density lipoprotein; MP, methylprednisolone; QUICKI, Quantitative Insulin Sensitivity Check Index; SBP, systolic blood pressure; TNF, tumour necrosis factor; VCAM, vascular adhesion molecule. *$P \leq 0.01$; **$P < 0.006$.

### Table 3 (Continued)

| Biomarker                          | Spearman Correlation Coefficient | *P* Value |
|-----------------------------------|----------------------------------|-----------|
| Polymorphonuclear cells ($\times 10^6/l$) | 0.041                            | -0.092    |
| Platelets ($10^9/l$)              | -0.025                           | 0.142     |
| Homocysteine ($\mu$mol/l)         | 0.124                            | 0.236     |
| Thyrotropin ($\mu$IU/ml)           | -0.132                           | 0.007     |
| LDL-cholesterol (mmol/l)          | -0.139                           | -0.078    |
| Apolipoprotein(a) (mg/l)          | 0.097                            | 0.004     |
| GFR (ml/min)                      | -0.285*                          | -0.144    |
| Urinary albumin/creatinine (mg/mmol) | -0.182                         | -0.163    |

DBP, diastolic blood pressure; ELAM, endothelial leukocyte adhesion molecule; ESR, erythrocyte sedimentation rate; GFR, glomerular filtration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; ICAM, intercellular adhesion molecule; IL, interleukin; LDL, low-density lipoprotein; MP, methylprednisolone; QUICKI, Quantitative Insulin Sensitivity Check Index; SBP, systolic blood pressure; TNF, tumour necrosis factor; VCAM, vascular adhesion molecule. *$P \leq 0.01$; **$P < 0.006$.
IL-1 and TNF-α are major proinflammatory cytokines in RA joints and stimulate IL-6 production by synovial fibroblasts [33-37], whereas IL-6 is a major circulating cytokine in RA that induces the acute phase response, production of immunoglobulins by B cells and neuroendocrine alterations [33,34,37,38]. IL-6 promotes adhesion molecule expression and stimulates macrophages to secrete monocyte chemotactic protein-1 [39]. Circulating IL-6 concentrations also predict cardiovascular disease in the general population, independent of hs-CRP levels [39].

Apart from IL-6, rheumatoid factor was also predictive of endothelial dysfunction independent of traditional cardiovascular risk factors in the present cohort. The mechanism underlying the strong association between rheumatoid factor and endothelial dysfunction in RA cannot be discerned from our

| Number of patients and biomarkers of endothelial dysfunction by sex, race, diabetes and medications used |
|-------------------------------------------------|----------------|----------------|----------------|
| Sex                                             | VCAM-1 (pg/ml) | ICAM-1 (pg/ml) | ELAM-1 (pg/ml) |
| Female                                          | 64             | 750 (391–2073) | 356 (135–993) | 58 (12–144) |
| Male                                            | 10             | 698 (463–1814) | 480 (235–805) | 60 (38–149) |
| Race                                            |                |                |                |
| Caucasian                                       | 68             | 750 (391–2073) | 366 (135–993) | 61 (12–149) |
| Asian                                           | 6              | 572 (463–971)  | 352 (235–699) | 49 (35–82)  |
| Diabetes                                        |                |                |                |
| Yes                                             | 5              | 674 (554–1338) | 376 (235–455) | 55 (52–129) |
| No                                              | 69             | 749 (391–2073) | 365 (135–993) | 59 (12–149) |
| COX-2 inhibitor use                             |                |                |                |
| Yes                                             | 20             | 689 (475–2073) | 371 (145–749) | 79 (25–129) |
| No                                              | 54             | 750 (391–2001) | 363 (135–993) | 55 (12–149) |
| Traditional NSAID use                           |                |                |                |
| Yes                                             | 19             | 766 (493–2001) | 366 (135–993) | 68 (16–149) |
| No                                              | 55             | 703 (391–2073) | 365 (145–761) | 55 (12–129) |
| Aspirin use                                     |                |                |                |
| Yes                                             | 6              | 719 (463–2073) | 346 (219–595) | 40 (23–94)  |
| No                                              | 68             | 747 (391–2001) | 366 (135–993) | 62 (12–149) |
| Oestrogen use                                   |                |                |                |
| Yes                                             | 24             | 673 (445–2001) | 311 (181–993) | 53 (12–83)  |
| No                                              | 50             | 786 (391–2073) | 389 (135–805) | 64 (20–149) |
| DMARD use                                       |                |                |                |
| Yes                                             | 56             | 726 (391–2073) | 368 (145–805) | 56 (12–149) |
| No                                              | 18             | 816 (567–2001) | 358 (135–993) | 64 (34–115) |
| Prednisone use                                  |                |                |                |
| Yes                                             | 11             | 930 (391–2073) | 455 (181–761) | 94 (23–129) |
| No                                              | 63             | 724 (445–2001) | 361 (135–993) | 55 (12–149) |
| Antihypertensive agent use                      |                |                |                |
| Yes                                             | 23             | 744 (569–2073) | 414 (219–805) | 66 (16–149) |
| No                                              | 51             | 758 (391–2001) | 350 (135–993) | 54 (12–137) |

Results for biomarkers are expressed as median (range). Data were analyzed using the Mann–Whitney U test. No comparisons were significant at P ≤ 0.01. COX-2, cyclooxygenase-2; DMARD, disease-modifying antirheumatic drug; ELAM, endothelial leukocyte adhesion molecule; ICAM, intercellular adhesion molecule; NSAID, nonsteroidal anti-inflammatory drug; VCAM, vascular adhesion molecule.
data. However, rheumatoid factor may directly cause endothelial injury [31]. Direct evidence for a role for humoral immunity in atherosclerosis was found by George and coworkers [40]. In their study repeated intraperitoneal administration of IgG from serum of mice immunized with heat shock protein 65 enhanced fatty streak formation in mice in comparison with their control anti-bovine serum albumin injected littermates [40]. Rheumatoid factor is produced by B cells that are highly effective at presenting antigens to T cells [41] and T-cell activation in rheumatoid synovium is B-cell dependent [42]. The recently reported remarkable efficacy of B-cell depletion in rheumatoid factor positive RA with rituximab [43] indicates that B cells are key contributors to the immunopathogenesis of RA. In a recent autopsy report on two RA patients with coronary artery disease the coronary plaques and adventitia contained large numbers of B cells, whereas in coronary artery disease it is typical for lymphocytic infiltrates to consist almost exclusively of T cells [44]. These reports and our findings support a role for humoral mechanisms in RA atherogenesis.

Finally, a low GFR also predicted endothelial dysfunction in our RA patients. Although only four (5%) patients had an elevated serum creatinine (>115 μmol/l), GFR estimation using the Cockcroft–Gault equation [45] revealed that 16 (22%) patients had a GFR under 60 ml/min [26], which is indicative of chronic kidney disease. The high prevalence of cardiovascular disease in individuals with chronic kidney disease has been amply reported [45]. This is attributable to the high prevalence of traditional risk factors such as older age, high total cholesterol, low high-density lipoprotein cholesterol and diabetes, as well as to nontraditional risk factors such as oxidant stress, inflammation and, to a lesser extent, hyperhomocysteinaemia. In the present cohort, varimax rotated factor analysis confirmed strong relationships between low GFR, age and hyperhomocysteinaemia [26]. Also, independent of age as well as other traditional cardiovascular risk factors, a low GFR remained independently predictive of endothelial dysfunction in our patients whereas hs-CRP was not associated with circulating adhesion molecules. In support of an important role of oxidant stress in cardiovascular disease complicating chronic kidney disease, both vitamin E 800 U daily and acetylcysteine 600 mg twice daily were shown to decrease cardiovascular events in randomized controlled trials in haemodialysis patients [45]. Whether such interventions could decrease cardiovascular disease in RA may deserve further study.

**Associations between biomarkers of endothelial dysfunction and common carotid artery intima–media thickness and plaque in RA patients**

In a previous study conducted by Wallberg-Jonsson and coworkers [23] in 39 RA patients, ICAM-1 and selectin concentrations were found to be related to ultrasonographically detected CCA and femoral artery plaque as well as to haemostatic factors of endothelial origin. We found that VCAM-1 was associated with ultrasonographically determined CCA IMT and plaque. Taken together, these data further support the contention that circulating adhesion molecules are linked to cardiovascular disease in RA.

**Study limitations**

We assessed cardiovascular risk comprehensively and our results are in keeping with previously reported paradigms of cardiovascular disease in RA [4,5,31]. However, our findings must be reproduced in a longitudinal study and investigations of a larger cohort is likely to reveal more independent associations between biomarkers of endothelial dysfunction and cardiovascular risk factors.

**Conclusion**

We found that the biomarkers of endothelial dysfunction VCAM-1, ICAM-1 and ELAM-1 were higher in 74 RA patients than in 80 healthy control individuals. In multivariable regression models these differences could be accounted for by nontraditional cardiovascular risk factors (high hs-CRP, IL-1, IL-6 and TNF-α) and unfavourable traditional cardiovascular risk factor profiles in RA patients. IL-6, rheumatoid factor titre and low GFR predicted endothelial dysfunction, as assessed by biomarkers, independent of traditional cardiovascular risk factor in the 74 RA patients. VCAM-1 was associated with CCA
atherosclerosis in RA. Those DMARDs that are most effective at suppressing both cytokine and rheumatoid factor produc-
tion may also be most effective in protecting against cardio-
vascular disease in RA. In addition, interventions aimed at
preserving renal function may need to be considered in cardi-
oxvascular disease prevention in RA.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
PD conceived the study, collected the data, performed the sta-
tistical analysis and drafted the manuscript. BJ participated in
the study design, interpretation of the data and drafting the
manuscript. SS conducted the immunoassays.

Acknowledgements
The authors thank Dr Milton Tobias for reading the radiographs, and Ms
Belinda Stevens for carrying out the ultrasonographic carotid artery eval-
uations. The study was supported in part by the South African Circu-
latory Disorders Research Fund.

References
1. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA,
Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity
and mortality in women diagnosed with rheumatoid arthritis. 
Circulation 2003, 107:1303-1307.
2. Wolfe F, Feinstein B, Straus WL: High incidence of cardiac and
 cerebrovascular disease prevalence in rheumatoid arthritis.
 J Rheumatol 2003, 30:36-40.
3. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: 
High incidence of cardiovascular events in a rheumatoid 
arthritis cohort not explained by traditional cardiac risk factors.
Arthritis Rheum 2001, 44:2737-2745.
4. Sattar N, McCaey DW, Capell H, McInnes IB: Explaining how 
'high-grade' systemic inflammation accelerates vascular risk in 
rheumatoid arthritis. Circulation 2003, 108:2957-2963.
5. Dessein PH, Joffe BI, Stanwix AE: Inflammation, insulin resistance, 
and aberrant lipid metabolism as cardiovascular risk factors 
in rheumatoid arthritis. J Rheumatol 2003, 30:1403-1405.
6. Wallberg-Jonsson S, Ohman ML, Dahliqvist SR: Cardiovascular 
morbidity and mortality in patients with seropositive rheuma-
toid arthritis in Northern Sweden. J Rheumatol 1997, 24:449-451.
7. Kumeda Y, Inaba M, Goto H, Nagata M, Henni Y, Furumiyya Y, I
ishima E, Inui K, Yutani Y, Miki T, Shoji T, Nishizawa Y: Increased 
thickness of the arterial intima-media detected by ultrasonon-
graphy in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1489-1497.
8. Nagata-Sakurai M, Inaba M, Goto H, Kumeda Y, Furumiyya Y, Inui 
K, Koyama H, Emoto M, Ishimura E, Shoji T, Nishizawa Y: Inflammation and bone resorption as independent factors of accel-
erated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:3061-3067.
9. Belcaro G, Nicolaides AN, Ramaswami G, Cesareone MR, De Sanctis M, Incandela L, Ferrari P, Geroulakos G, Barsotti A, Griffin 
M, et al.: Carotid and femoral ultrasound morphology screening 
and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVES study (1)). Atherosclerosis 2001, 156:379-387.
10. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction. A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
11. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, 
Llorna J, Vidan J, Hajeer AH, Ollier WE, Matthey DL, Gonzalez-Gay MA: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003, 114:847-852.
12. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, 
Piro M, Shoentfeld Y, Schiliaci G, Mannarino E: Endothelial dys-
fuction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004, 63:31-35.
13. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, 
Bechir M, Spieker LE, Neidhart M, Michel BA, et al.: Anti-tumor 
nectrosis factor-alpha treatment improves endothelial function in 
patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
14. Bergholm R, Leirisalo-Repo M, Vehkaaara S, Makimattila S, Taski-
en MR, Yki-Jarvinen H: Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterio-
scler Thromb Vasc Biol 2002, 22:1837-1841.
15. Van Doornum S, McColl G, Jenkins A: Screening for atheroscle-
rosis in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:72-80.
16. Solomon DH, Hu FB, Rifaï N, Manson JE: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986.
17. Ponthieux A, Herbeth B, Drouesch S, Haddy N, Lambert D, Visvikis 
S: Biological determinants of serum ICAM-1, E-selectin, P-
selectin and L-selectin levels in healthy subjects: the Stanislas 
study. Atherosclerosis 2004, 172:299-308.
18. Hwang S-J, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, 
Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules 
VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and 
incident coronary heart disease cases. Circulation 1997, 
96:4219-4225.
19. De Caterina R, Basta G, Lazzerini G, Dell’Omo G, Petrucci R, 
Mora C, Carmassi F, Pedrinielli R: Soluble vascular cell adhe-
sion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:2646-2654.
20. O’Malley T, Luddman CA, Riemersma RA, Fox KA: Early increase in 
levels of soluble inter-cellular adhesion molecule-1 (sICAM-
1): potential risk factor for the acute coronary syndromes. Eur 
Heart J 2001, 22:1226-1234.
21. Maik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, 
Lennon L, Thomson A, Haskard D: Soluble adhesion molecules 
and prediction of coronary heart disease: a prospective study 
and meta-analysis. Lancet 2001, 358:971-976.
22. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW: 
Cardiovascular risk factors in women with and without rheu-
matoid arthritis. Arthritis Rheum 2004, 50:3444-3449.
23. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Ran-
tapaa-Dahliqvist S: Activation of the immune system and inflam-
matory activity in relation to markers of atherothrombotic 
disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002, 29:875-882.
24. Cush JJ, Rothlein R, Lindseth HB, Mainolfi EA, Lipsky PE: 
Increased levels of circulating intercellular adhesion molecule 
1 in the sera of patients with rheumatoid arthritis. Arthritis 
Rheum 1993, 36:1098-1102.
25. Annett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper 
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American 
Rheumatism Association 1987 revised criteria for the classifi-
cation of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
26. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K,
Stanwix AE: Traditional and non-traditional cardiovascular risk 
factors are associated with atherosclerosis in rheumatoid 
arthritis. J Rheumatol 2008, 35:1447-1454.
27. Dessein PH, Joffe BI, Stanwix AE: Subclinical hypothyroidism is 
associated with insulin resistance in rheumatoid arthritis. Thy-
roid 2004, 14:443-446.
28. Veale DJ, Maple C, Kirk G, McLaren M, Belch J: Soluble cell 
adhesion molecules-P-selectin and ICAM-1, and disease activity 
in patients receiving sulphasalazine for active rheuma-
toid arthritis. Scand J Rheumatol 1998, 27:296-299.
29. Em A, Ashour S, Moustaia H, Ahmed I: Altered levels of soluble 
adhesion molecules in patients with rheumatoid arthritis com-
plicated by peripheral neuropathy. J Rheumatol 2002, 29:57-61.
30. Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheu-
matoid arthritis versus osteoarthritis: acute phase response 
related decreased insulin sensitivity and high-density lipoprotein 
cholesterol as well as clustering of metabolic syndrome features 
in rheumatoid arthritis. Arthritis Res 2002, 4:R5.
31. Van Doornum S, McColl G, Wicks IP: Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? *Arthritis Rheum* 2002, 46:862-783.

32. Wolfe F: Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. *J Rheumatol* 1997, 24:1477-1485.

33. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol* 1996, 14:397-440.

34. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. *Ann Intern Med* 1998, 128:127-137.

35. Duff GW: Cytokines and acute phase proteins in rheumatoid arthritis. *Scand J Rheumatol Suppl* 1994, 100:9-19.

36. Ou LS, See LC, Wu CJ, Kao CC, Lin YL, Huang JL: Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. *Clin Rheumatol* 2002, 21:52-56.

37. Maini RN, Feldman M: How does infliximab work in rheumatoid arthritis? *Arthritis Res* 2002;22-28.

38. Barrera P, Boerbooms AM, Demacker PN, van de Putte LB, Gallati H, van der Meer JW: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. *Br J Rheumatol* 1994, 33:1017-1024.

39. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P: C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? *J Hypertens* 2003, 21:1787-1803.

40. Edwards JC, Szczepanski L, Szczepanska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* 2004, 350:2572-2581.

41. Aurbry MC, Riehle DL, Edwards WD, Maradit-Kremers H, Roger Hawkins T, Gabrielson SE: B-lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. *Cardiovasc Pathol* 2004, 13:233-236.

42. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culeton B, Hamm LL, McCullough PA, Kasiski BL, Kelepouris E. et al.: American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease. *Circulation* 2003, 108:2154-2169.